1. Home
  2. MCHX vs ASRT Comparison

MCHX vs ASRT Comparison

Compare MCHX & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marchex Inc. Class B

MCHX

Marchex Inc. Class B

N/A

Current Price

$1.65

Market Cap

71.6M

ML Signal

N/A

Logo Assertio Holdings Inc.

ASRT

Assertio Holdings Inc.

HOLD

Current Price

$0.73

Market Cap

75.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCHX
ASRT
Founded
2003
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
71.6M
75.1M
IPO Year
2004
1997

Fundamental Metrics

Financial Performance
Metric
MCHX
ASRT
Price
$1.65
$0.73
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
21.8K
313.9K
Earning Date
11-13-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$46,494,000.00
$137,354,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$6.70
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
9.22
52 Week Low
$1.26
$0.51
52 Week High
$2.31
$1.01

Technical Indicators

Market Signals
Indicator
MCHX
ASRT
Relative Strength Index (RSI) 58.69 41.47
Support Level $1.60 $0.75
Resistance Level $1.69 $0.80
Average True Range (ATR) 0.08 0.04
MACD 0.01 -0.00
Stochastic Oscillator 93.75 23.22

Price Performance

Historical Comparison
MCHX
ASRT

About MCHX Marchex Inc. Class B

Marchex Inc harnesses the power of AI and conversational intelligence to provide actionable insights aligned with prescriptive vertical market data analytics, driving operational excellence and revenue acceleration. Marchex enables executive, sales, and marketing teams to optimize customer journey experiences across communications channels, enabling enterprise strategies, empowering businesses to increase revenue through informed decision-making and strategic execution.

About ASRT Assertio Holdings Inc.

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

Share on Social Networks: